drugset
drugset / Trial / NCT07011004

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

NCT07011004 ↗

Phase 1 Recruiting 18 enrolled Memorial Sloan Kettering Cancer Center Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.

Timeline

Start
2025-05-30
Primary completion
2028-05
Completion
2028-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody — Intravenous
Subject CIML-NK cell therapy Cell therapy — Intravenous
Background aldesleukin Protein / enzyme biologic — Subcutaneous

Indications

acute myeloid leukemia